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Abstract
Background
Optimally treated heart failure (HF) patients often have persisting symptoms and poor
health-related quality of life. Comorbidities are common, but little is known about their impact
on these factors, and guideline-driven HF care remains focused on cardiovascular status.
The following hypotheses were tested: (i) comorbidities are associated with more severe
symptoms and functional limitations and subsequently worse patient-rated health in HF, and
(ii) these patterns of association differ among selected comorbidities.
Methods and findings
The Swedish Heart Failure Registry (SHFR) is a national population-based register of HF
patients admitted to >85% of hospitals in Sweden or attending outpatient clinics. This study
included 10,575 HF patients with patient-rated health recorded during first registration in the
SHFR (1 February 2008 to 1 November 2013). An a priori health model and sequences-of-
regressions analysis were used to test associations among comorbidities and patient-
reported symptoms, functional limitations, and patient-rated health. Patient-rated health
measures included the EuroQol–5 dimension (EQ-5D) questionnaire and the EuroQol visual
analogue scale (EQ-VAS). EQ-VAS score ranges from 0 (worst health) to 100 (best health).
Patient-rated health declined progressively from patients with no comorbidities (mean EQ-
VAS score, 66) to patients with cardiovascular comorbidities (mean EQ-VAS score, 62) to
patients with non-cardiovascular comorbidities (mean EQ-VAS score, 59). The relationships
among cardiovascular comorbidities and patient-rated health were explained by their asso-
ciations with anxiety or depression (atrial fibrillation, odds ratio [OR] 1.16, 95% CI 1.06 to
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1.27; ischemic heart disease [IHD], OR 1.20, 95% CI 1.09 to 1.32) and with pain (IHD, OR
1.25, 95% CI 1.14 to 1.38). Associations of non-cardiovascular comorbidities with patient-
rated health were explained by their associations with shortness of breath (diabetes, OR
1.17, 95% CI 1.03 to 1.32; chronic kidney disease [CKD, OR 1.23, 95% CI 1.10 to 1.38;
chronic obstructive pulmonary disease [COPD], OR 95% CI 1.84, 1.62 to 2.10) and with
fatigue (diabetes, OR 1.27, 95% CI 1.13 to 1.42; CKD, OR 1.24, 95% CI 1.12 to 1.38;
COPD, OR 1.69, 95% CI 1.50 to 1.91). There were direct associations between all symp-
toms and patient-rated health, and indirect associations via functional limitations. Anxiety or
depression had the strongest association with functional limitations (OR 10.03, 95% CI 5.16
to 19.50) and patient-rated health (mean difference in EQ-VAS score, −18.68, 95% CI
−23.22 to −14.14). HF optimizing therapies did not influence these associations. Key limita-
tions of the study include the cross-sectional design and unclear generalisability to other
populations. Further prospective HF studies are required to test the consistency of the rela-
tionships and their implications for health.
Conclusions
Identification of distinct comorbidity health pathways in HF could provide the evidence for indi-
vidualised person-centred care that targets specific comorbidities and associated symptoms.
Author summary
Why was this study done?
• Heart failure is an increasingly common condition, and patients often experience persis-
tent symptoms and poor quality of life, even when they are receiving the best possible
treatment for their heart failure.
• Most heart failure patients have other conditions that dominate their health experience,
yet heart failure treatment focuses on their cardiovascular status.
• There is a lack of understanding about the relationships among different comorbidities
and quality of life in heart failure, which are important to guide individualised treatment
plans for patients.
What did the researchers do and find?
• We used an established health-related quality of life model to develop and test a new
heart failure health model that included the most common heart failure comorbidities.
• We tested this model by examining the postulated relationships among comorbidities,
symptoms and functional limitations reported by patients, and their overall health expe-
rience, using a national register of heart failure patients in Sweden.
• We found that non-cardiovascular comorbidities were associated with much higher
overall symptom burden and more severe symptoms than cardiovascular comorbidities.
Comorbidity health pathways in heart failure patients
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• Predominant symptoms for cardiovascular comorbidities were pain and anxiety,
whereas for non-cardiovascular comorbidities they were shortness of breath and
fatigue.
• Heart failure optimising therapies did not influence these symptoms, functional limita-
tions, or quality of life.
What do these findings mean?
• Current guidelines in heart failure focus on improving cardiovascular status in response
to common heart failure symptoms (shortness of breath, fatigue, and leg swelling).
• Our study shows that for some patients, these symptoms might be driven by non-car-
diovascular conditions such as diabetes and renal disease, rather than their cardiovascu-
lar status. We found that cardiovascular comorbidities were more likely to be associated
with pain and anxiety than shortness of breath or fatigue.
• To improve health-related quality of life, heart failure guideline-driven care needs to
include optimal management of the most prevalent non-cardiovascular comorbidities
and routine management of pain and anxiety or depression.
• To provide individualised patient care, guidelines need to better align symptoms with
the cardiovascular and non-cardiovascular status of the patient.
Introduction
Heart failure (HF) is a complex clinical syndrome of multiple symptoms, functional impair-
ments, and poor health-related quality of life (HRQoL). With modern therapies, HF patients are
now living longer but with a potentially higher symptom burden [1] that can be worse compared
to people with other chronic diseases including cancer [2]. Inadequate symptom control and
poor HRQoL are significant drivers of hospitalisations, readmissions, and death in HF [3,4].
HF patients are usually older, with a high number of comorbidities, and a third of patients
report that other medical conditions dominate their health experience [5], yet guideline-driven
symptom management in HF focuses on cardiovascular status [6]. Persisting symptoms and poor
HRQoL after optimisation of HF treatments [7] suggest that comorbidities may be an important
determinant of health and that non-cardiovascular comorbidities may be associated with HF-
related symptoms [8]. However, the evidence is inconsistent, with some HF studies showing asso-
ciations between comorbidities and HRQoL [9–11] and others showing no such associations
[12,13]. Whilst comorbidities are consistent predictors of morbidity and mortality in HF [14],
their interrelationships with symptoms, functional limitations, and overall health have not been
explored. We used the Swedish Heart Failure Registry (SHFR), which is one of the largest popula-
tion-based HF registers, to routinely collect patient-reported outcomes [15] to investigate the
interplay among HF comorbidities, symptoms, functional limitations, and patient-rated health.
Methods
Study population
The SHFR is a national population-based register of all HF patients admitted to hospitals or
attending outpatient clinics in participating primary care units [15]. The register collects
Comorbidity health pathways in heart failure patients
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HRQoL data measured using the EuroQol–5 dimension (EQ-5D) questionnaire, including the
EuroQol visual analogue scale (EQ-VAS), at baseline registration, as well as patient demo-
graphics and clinical and healthcare information. We obtained first entry data for all HF
patients included in the SHFR from 1 February 2008 to 1 November 2013 with EQ-5D
recorded at baseline.
Establishment of the registry and analysis of data were approved by a multisite ethics com-
mittee and conform to the Declaration of Helsinki. Individual patient consent is not required,
but patients are informed of entry into national registries and can opt out. Access to the SHFR
was granted following project approval (S1 Proposal) by the SwedeHF Research Board. The
original statistical analysis plan was based on standard linear and logistic regression analyses.
The sequences-of-regressions approach was adopted at the early stages of data acquisition to
provide a novel method of analysis to deal effectively with the complexity underlying the anal-
ysis of postulated relationships among many variables. This study is reported as per the
RECORD guidelines (S1 Checklist).
Model of HF pathways to patient-reported outcomes
Previously, an a priori model by Wilson and Cleary [16] hypothesized a potential pathway
from chronic disease to patient-reported outcomes and patient-rated health. The model pro-
poses a pathway of linkages between 5 domains: (i) bio-physiological status, (ii) symptoms,
(iii) functional status, (iv) general health perception (i.e., patient-rated health), and (v) quality
of life (Fig 1). We used this concept to develop a HF health model with a focus on comorbidi-
ties to test the hypothesis that the potential mechanisms underlying health in HF differ among
selected comorbidities. We included cardiovascular conditions related to the aetiology of HF
(defined as cardiovascular comorbidities) to compare with other, non-cardiovascular comor-
bidities. Wilson and Cleary’s model has since been adapted to take account of patient and envi-
ronmental factors that might influence any stage of the model, including bio-physiological
status [17]. We used this adapted version, given the clear link between these factors and the
development of both HF and comorbidities in older age. All variables selected to include in the
model were chosen by an expert group including HF specialists (Fig 2). The overall domains
within the postulated pathway were (i) patient and environmental factors to (ii) comorbidities
to (iii) left ventricular ejection fraction to (iv) symptoms to (v) functional limitations to (vi)
patient-rated health. We tested the direct relationships between the individual domains and
Fig 1. Wilson and Cleary’s health-related quality of life conceptual model. Wilson and Cleary’s model for health-related quality of life [16], revised with permission
from JAMA [17]. Wilson and Cleary’s general conceptual model of health links objective biological measurements to the subjective consequences of disease as perceived
by patients. In this model, Wilson and Cleary propose causal linkages between 5 health domains: bio-physiological status, symptoms, functional status, general health
perception, and quality of life. The arrows represent dominant causal relationships. Reciprocal relationships between the variables are recognised to exist but are not
represented, and we did not consider these. The revised version extends the influence of individual and environmental characteristics to all health domains in the model.
https://doi.org/10.1371/journal.pmed.1002540.g001
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patient-rated health and the indirect relationships that were explained by intermediary
domains. We did not include the final domain in Wilson and Cleary’s model (overall quality
of life), as this includes non-health-related factors.
Patient and environmental factors
HF patient factors were age, sex, marital status (single or married/partner), body mass index
(BMI), smoking status (current or former/none), HF duration (6 or <6 months), heart rate,
haemoglobin, devices, and prescription of HF optimising drugs (beta blockers, angiotensin
converting enzyme inhibitors [ACEis], angiotensin II receptor blockers [ARBs]) and diuretics.
Environmental factors were healthcare provider (inpatient or outpatient) and speciality (cardi-
ology or medicine). Of the continuous variables, age and heart rate values were all within the
plausible range, and BMI and haemoglobin were truncated at the boundaries of their respec-
tive plausible ranges (<10 values truncated in total).
Bio-physiological status
HF biological status was based on left ventricular ejection fraction defined as reduced (<40%),
midrange (40%–49%), or preserved (50%). For the sequences of regressions analyses, ejec-
tion fraction was dichotomised as40% or <40%. Cardiovascular comorbidities were hyper-
tension, dilated cardiomyopathy (DCM), valve disease, atrial fibrillation (AF), and ischemic
heart disease (IHD), and non-cardiovascular comorbidities were diabetes, chronic obstructive
pulmonary disease (COPD), and chronic kidney disease (CKD). CKD was defined by an esti-
mated glomerular filtration rate of<60 ml/min/1.73 m2.
Symptoms and functional limitations
Previous evidence has shown only weak associations between HF biological status and short-
ness of breath (SOB) [18–20], but the influence of other conditions or symptoms on this rela-
tionship has not been considered. Two of the most frequently reported HF symptoms are SOB
and fatigue [21]. However, HF patients also commonly experience pain and low mood
[8,21,22], and these symptoms negatively impact functional performance [23]. So, for the
symptoms domain, we included pain and anxiety or depression dimensions from the EQ-5D
Fig 2. Hypothetical HF health model. Model based on a revised version of Wilson and Cleary’s health-related quality of life conceptual model [16,17]. The arrows
represent direct relationships for patient and environmental factors as well as 4 of the 5 health domains: bio-physiological status (comorbidities), symptoms, functional
status, and general health perception. Only arrows between adjacent domains are displayed, but it is postulated that each domain may have other direct relationships
with any of the proceeding domains, and patient and environmental factors are related to every domain. ACEi, angiotensin converting enzyme inhibitor; ARB,
angiotensin II receptor blocker; EQ-VAS, EuroQol–5 dimension visual analogue scale; HF, heart failure.
https://doi.org/10.1371/journal.pmed.1002540.g002
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questionnaire, together with patient-reported SOB and fatigue. For functional limitations, the
‘usual activities’ EQ-5D dimension was selected, which is most inclusive of a range of physical,
emotional, and social functions. SOB and fatigue were dichotomised as ‘no or slight’ and
‘marked or severe’, and pain, anxiety or depression, and functional limitations were dichoto-
mised as ‘no problems’ or ‘any problems’.
Patient-rated health
Patient-rated health is a known predictor of mortality in HF [24]. In this study, patient-rated
health was based on the EQ-VAS, which is a numerical scale from 0 (worst health imaginable)
to 100 (best health imaginable) [25]. The EQ-5D is valid, comparable to other general [26] and
specific quality of life tools [27], and widely used in HF clinical trials [9].
Statistical analysis
Descriptive analysis. We dichotomised patient-rated health (EQ-VAS) at the population
mean (worse health and better health) to describe patient and clinical characteristics in a con-
tingency table. Summary statistics are means and standard deviations for continuous data with
symmetrical distribution, whilst skewed continuous data are described by medians with inter-
quartile ranges. Dichotomous data are summarised by frequencies and percent prevalence.
Sequences-of-regressions analysis. We used sequences of regressions [28], a subclass of
graphical Markov models, to estimate the associations between HF comorbidities and patient-
rated health, separating direct from indirect associations via symptom burden and functional
limitations. This is a multivariate statistical technique that extends path analysis and provides a
novel strategy for describing complex interrelations by jointly modelling multiple outcomes
and background factors (S1 Methods). The model was built by fitting ordered sequences of
logistic or linear regression models for each variable in the different domains organised a pri-
ori into the HF health model (Fig 2). Each variable in turn, starting with patient-rated health
and working backwards, was fitted into a regression model with all the variables to its left-
hand side. The regression model that best described the data was selected by comparing nested
models with different combinations of explanatory variables. The aim of the model was to par-
tition the total effects of cardiovascular and non-cardiovascular comorbidities, left ventricular
ejection fraction, symptoms, and functional limitations on patient-rated health into direct
effects (not explained by any of the intermediary factors) and indirect effects (partially
explained by intermediary factors such as symptoms and functional limitations). These path-
ways of association are represented in regression graphs that display all the variables, with two
variables linked by an arrow if they are associated. An arrow emerging from a selected explana-
tory variable and pointing to a response variable represents a direct association. A sequence of
connected arrows between 2 variables represents an indirect association. Partial regression
coefficients were used to quantify the relative importance of the associations depicted by the
arrows in the graph. All response variables except EQ-VAS are binary, thus odds ratios (ORs)
with 95% confidence intervals for these are reported. For EQ-VAS as the response variable, the
partial regression coefficients represent the mean differences in score for a 1-unit increase in
the explanatory variable, and these are reported with 95% CIs.
To check for non-linear terms in the regression models, quadratic or interaction terms
were included whenever these were highlighted by screening plots appropriate for checking
the assumptions of the multivariate normal distribution. The level of statistical significance
was set at P< 0.01, and analyses were performed using StataMP 13. There were very small pro-
portions of missing values for a few explanatory and intermediate variables (Table 1); these are
Comorbidity health pathways in heart failure patients
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unlikely to bias the estimation of the model, which used all the data available when estimating
single regression models, thus assuming a missing at random mechanism.
Table 1. Characteristics by patient-rated health.
Characteristic Total (N = 10,575) Worse patient-rated health (N = 5,430) Better patient-rated health (N = 5,145) Missing (%)
Patient and environmental factors
Age, years 74 [65–81] 75 [67–81] 72 [64–80] —
Women 3,473 (32.8) 1,957 (36.0) 1,516 (29.5) —
Single 3,958 (38.6) 2,205 (41.7) 1,753 (35.3) 3.1
Body mass index 26.7 [24–30] 26.7 [24–30] 26.7 [24–30] 4.6
Current smoker 1,202 (12.6) 655 (13.5) 547 (11.7) 10.0
Haemoglobin, g/l 134 ± 17 133 ± 17 136 ± 16 0.03
Ejection fraction 8.5
<40% 6,031 (62.3) 3,078 (62.2) 2,953 (62.5)
40%–49% 2,126 (22.0) 1,034 (20.9) 1,092 (23.1)
50% 1,517 (15.7) 835 (16.9) 682 (14.4)
Heart failure 6 months 5,161 (49.1) 2,873 (53.2) 2,288 (44.7) 0.6
Heart rate 72.4 ± 14.7 73.3 ± 14.8 71.5 ± 14.6 0.01
Beta blocker 9,330 (88.5) 4,788 (88.6) 4,452 (88.5) 0.4
ACEi or ARB 9,520 (90.4) 4,812 (89.1) 4,708 (91.7) 0.4
Diuretic 8,138 (77.4) 4,446 (82.4) 3,692 (72.1) 0.6
Device 1,440 (13.8) 772 (14.4) 668 (13.1) 1.2
Cardiology care 5,506 (59.5) 2,731 (57.3) 2,775 (61.7) 12.5
Inpatient 2,746 (26.0) 1,466 (27.0) 1,280 (24.9) —
Comorbidities
Ischemic heart disease 5,418 (53.9) 2,696 (52.4) 2,181 (44.5) 5.0
Atrial fibrillation 5,064 (48.1) 2,739 (50.7) 3,325 (45.4) 0.5
Hypertension 5,311 (51.5) 2,745 (52.1) 2,566 (51.0) 2.5
Dilated cardiomyopathy 1,599 (15.7) 750 (14.4) 849 (17.1) 3.5
Valve disease 603 (5.8) 322 (6.0) 281 (5.5) 1.3
Diabetes 2,518 (23.9) 1,447 (26.8) 1,071 (20.9) 0.5
Chronic obstructive pulmonary disease 1,813 (17.4) 1,101 (20.7) 712 (14.0) 1.7
Chronic kidney disease 4,646 (43.9) 2,619 (48.2) 2,027 (39.4) —
Symptoms
Shortness of breath 7.4
Any 8,354 (85.3) 4,623 (92.7) 3,731 (77.7)
Marked or severe 3,475 (35.0) 2,528 (50.7) 947 (19.7)
Fatigue 7.5
Any 8,281 (84.6) 4,648 (93.1) 3,633 (75.8)
Marked or severe 3,400 (34.7) 2,494 (49.9) 906 (18.9)
Pain (any) 5,065 (51.9) 3,206 (64.4) 1,859 (38.9) 7.8
Anxiety or depression (any) 4,336 (44.6) 2,932 (59.2) 1,404 (29.4) 8.0
Functional limitations (usual activities) 3,636 (37.2) 2,619 (52.6) 1,017 (21.3) 7.7
Patient-rated health 62.6 ± 19.9 47.2 ± 14.0 78.8 ± 9.7 —
Data are expressed as frequency (%), mean ± standard deviation, or median [interquartile range] (for variables with skewed distribution).
Patient-rated health was determined by the EuroQol visual analogue scale. Patients rated their health from 0 (worst imaginable health state) to 100 (best imaginable
health state). We dichotomised this at the mean value (<63,63) to describe ‘worse’ and ‘better’ patient-rated health for our sample.
Defined by estimated glomerular filtration rate < 60 ml/min/1.73 m2.
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
https://doi.org/10.1371/journal.pmed.1002540.t001
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Results
Study population characteristics
There were 10,575 HF patients with EQ-VAS recorded at inclusion in the register, and patient
characteristics are presented in Table 1 (comparison to patients in the overall register includ-
ing those without EQ-VAS recorded can be seen in S1 Table). Median age was 74 years (IQR
65–81), and 33% were women. A quarter (26%) of patients were inpatients, and most (90%)
were prescribed HF optimising drug therapies. Prevalence of symptoms and functional limita-
tions was high, with 85% patients experiencing SOB and fatigue and over a third (35%) report-
ing marked or severe intensity of both symptoms. Approximately half reported pain (52%)
and anxiety (45%). Functional limitations were reported by 37% of HF patients, and the mean
EQ-VAS score was 63 (SD 20).
Cardiovascular and non-cardiovascular comorbidities
The prevalence of cardiovascular comorbidities was high, with half of HF patients having AF
(48%), hypertension (52%), and IHD (54%). Non-cardiovascular comorbidities were also fre-
quent: 44% of patients had CKD, 17% had COPD, and 24% had diabetes. There were 415
(3.9%) HF patients without any comorbidities. These patients were on average 10 years youn-
ger, mostly outpatients (83%), and much more likely to have shorter duration of HF (<6
months) than HF patients with comorbidities (82% versus 50%). The prevalence of symptoms
and functional limitations was higher for HF patients with comorbidities than for those with-
out and differed between those with cardiovascular and non-cardiovascular comorbidities, as
shown in Fig 3.
There was a marked increase in the prevalence of symptoms and functional limitations
from HF patients with no comorbidities to those with cardiovascular comorbidities to those
with non-cardiovascular comorbidities. Respectively, mean prevalence among the 3 comorbid-
ity categories was 26%, 37%, and 46% for marked or severe SOB; 27%, 36%, and 44% for
Fig 3. Prevalence of symptoms and functional limitations in heart failure by comorbidity. Shortness of breath (SOB) and fatigue show patients with marked or
severe symptoms. Pain, anxiety or depression, and functional limitations show patients with ‘any’. AF, atrial fibrillation; CKD, chronic kidney disease; COPD, chronic
obstructive pulmonary disease; IHD, ischemic heart disease.
https://doi.org/10.1371/journal.pmed.1002540.g003
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marked or severe fatigue; 45%, 52%, and 59% for pain; 42%, 46%, and 48% for anxiety or
depression; and 28%, 38%, and 45% for functional limitations. Patient-rated health showed a
similar pattern (Fig 4), where mean EQ-VAS score progressively declined from no comorbidi-
ties (mean EQ-VAS score, 66) to cardiovascular comorbidities (mean EQ-VAS score, 62) to
non-cardiovascular comorbidities (mean EQ-VAS score, 59).
Direct associations between all variables and patient-rated health
Summaries of the sequences of regressions fitted for the HF health model are presented in
Tables 2 and S2. Patient-rated health (EQ-VAS score, 1 to 100) was directly explained by a
combination of patient and environmental factors, symptoms, and functional limitations.
These factors collectively explained 32% of the variance in patient-rated health (coefficient of
multiple determination R2 = 0.32, 95% CI 0.31 to 0.34). There were direct negative associations
with patient-rated health for older age, single status, longer HF duration, higher heart rate, pre-
scribed diuretic, being an inpatient, having diabetes, and having symptoms and functional lim-
itations. Care under cardiology compared to general medicine was associated with better
patient-rated health (mean difference in EQ-VAS score, 1.28, 95% CI 0.54 to 2.03). Two of the
strongest direct associations with worse patient-rated health were anxiety or depression (mean
difference in EQ-VAS score, −18.68, 95% CI −23.2 to 14.1) and functional limitations (mean
difference in EQ-VAS score, −7.51, 95% CI −8.37 to −6.65). Whilst most comorbidities had
significant crude associations with patient-rated health (S3 Table), they did not have direct
associations with patient-rated health once other variables including symptoms and functional
limitations were considered, except for diabetes.
Indirect associations between HF comorbidities and patient-rated health
For simplicity of presentation, the indirect pathways between comorbidities and patient-rated
health are displayed in 2 graphs (cardiovascular comorbidities in Fig 5 and non-cardiovascular
comorbidities in Fig 6). Individual and environmental factors are not displayed.
Fig 4. Patient-rated health (EQ-VAS) in heart failure by comorbidity. EQ-VAS was based on patient-rated health ranging from 0 (worse imaginable health state),
100 (best imaginable health state). COPD, chronic obstructive pulmonary disease; EQ-VAS, EuroQol–5 dimension visual analogue scale; IHD, ischaemic heart disease.
https://doi.org/10.1371/journal.pmed.1002540.g004
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Table 2. Selected regression models describing direct and indirect associations between health factors.
Explanatory variable Dependent variable (outcome for each model)
SOB,
OR (95% CI)
Fatigue,
OR (95% CI)
Pain,
OR (95% CI)
Anxiety or
depression,
OR (95% CI)
Functional
limitations,
OR (95% CI)
Patient-rated health,
relative mean
difference (95% CI)
Age (per year) 1.01 (1.01, 1.02) 1.02 (1.01, 1.03) 1.01 (1.01, 1.02) 0.99 (0.98, 0.99) 1.02 (1.01, 1.03) −0.08 (−0.13, −0.04)
Women 3.48 (1.72, 7.03) 1.39 (1.25, 1.54) 1.61 (1.46, 1.78) 1.17 (1.06, 1.30)
Single −1.58 (−2.33, −0.83)
Body mass index 1.04 (1.03, 1.05) 1.02 (1.02, 1.03) 1.04 (1.03, 1.05)
Current smoker 1.19 (1.01, 1.39) 1.26 (1.09, 1.47) 1.40 (1.21, 1.62) 1.21 (1.05, 1.39)
Haemoglobin 0.93 (0.90, 0.96) 0.94 (0.91, 0.97) 0.90 (0.88, 0.93) 0.95 (0.93, 0.98)
Heart failure 6 months 1.39 (1.25, 1.54) 1.23 (1.11, 1.36) 1.18 (1.07, 1.30) −1.33 (−2.08, −0.58)
Heart rate 1.01 (1.01, 1.01) 1.01 (1.00, 1.01) −0.05 (−0.08, −0.03)
Beta blocker
ACEi or ARB 0.70 (0.59, 0.82)
Diuretic 1.94 (1.67, 2.24) 1.61 (1.41, 1.85) 1.29 (1.15, 1.44) 1.40 (1.25, 1.57) 1.34 (1.18, 1.52) −1.42 (−2.35, −0.49)
Device 1.26 (1.09, 1.45)
Cardiology 0.82 (0.74, 0.92) 1.28 (0.54, 2.03)
Inpatient 1.35 (1.20, 1.51) 1.44 (1.29, 1.60) 1.24 (1.11, 1.37) 1.28 (1.15, 1.44) −2.04 (−2.87, −1.21)
Comorbidities
Ischemic heart disease 1.25 (1.14, 1.38) 1.20 (1.09, 1.32)
Atrial fibrillation 1.16 (1.06, 1.27)
Hypertension
Dilated cardiomyopathy
Valve surgery
Diabetes 1.17 (1.03, 1.32) 1.27 (1.13, 1.42) −1.33 (−2.20, −0.47)
COPD 1.84 (1.62, 2.10) 1.69 (1.50, 1.91) 1.34 (1.19, 1.52) 1.21 (1.08, 1.36) 1.22 (1.08, 1.38)
Chronic kidney disease 1.23 (1.10, 1.38) 1.24 (1.12, 1.38)
Ejection fraction <40%
Symptoms
Shortness of breath 1.98 (1.74, 2.26) −6.24 (−7.30, −5.18)
Fatigue 2.45 (2.16, 2.79) −5.53 (−6.61, −4.45)
Pain 2.33 (2.10, 2.58) −4.51 (−5.31, 3.71)
Anxiety or depression 10.03 (5.16, 19.50) −18.68 (−23.22, −14.14)
Functional limitations
(problems with usual
activities)
−7.51 (−8.37, −6.65)
Non-linear effects and
interactions
Age (per year) and female 0.99 (0.98, 0.99)
Age (per year) and anxiety
or depression
0.98 (0.97, 0.99) 0.15 (0.08, 0.21)
The models were built by fitting ordered sequences of logistic or linear regression models for each variable adjusted by all the variables to their left-hand side in the HF
health model (Fig 2). Where variables were in domains of multiple outcomes, e.g., symptoms, they were regressed on variables to their left that were not in the same
domain. Variables in the same domain or to the right of the outcome variable are noted by grey shading as these would not be relevant for that component of the model.
For each outcome, the regression model that best described the data was selected by comparing nested models with different combinations of explanatory variables.
Patient-rated health was based on EuroQol visual analogue scale, where patients rate their health from 0 (worst imaginable health state) to 100 (best imaginable health
state).
Defined by estimated glomerular filtration rate < 60 ml/min/1.73 m2.
Pain, anxiety, and functional limitations were ‘any’ compared to none, and shortness of breath and fatigue were ‘marked or severe’ compared to ‘none or slight’.
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD; chronic obstructive pulmonary disease.
https://doi.org/10.1371/journal.pmed.1002540.t002
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Cardiovascular comorbidities and patient-rated health
Whilst none of the cardiovascular comorbidities had a direct association with patient-rated
health, 2 had indirect associations through pain, anxiety or depression, and functional limita-
tions (Fig 5). There were no associations between any of the cardiovascular comorbidities and
SOB or fatigue. The association between AF and patient-rated health was explained by an
increased risk of anxiety or depression (OR 1.16, 95% CI 1.06 to 1.27), which in turn was asso-
ciated with increased risk of functional limitation (OR 10.03, 95% CI 5.2 to 19.5) and subse-
quently worse patient-rated health (mean difference in EQ-VAS score, −7.51, 95% CI −8.37 to
−6.65). IHD was associated with pain (OR 1.25, 95% CI 1.14 to 1.38) and anxiety or depression
(OR 1.20, 95% CI 1.09 to 1.32), which were both associated with functional limitations and
subsequent worse patient-rated health. There were also direct associations between pain and
worse patient-rated health (mean difference in EQ-VAS score, −4.51, 95% CI −5.31 to −3.71)
and anxiety or depression and worse patient-rated health (mean difference in EQ-VAS score,
−18.68, 95% CI −23.22 to −14.14) that were not explained by functional limitations. DCM,
hypertension, and valve disease in HF were not associated directly or indirectly with symp-
toms, functional limitations, or patient-rated health. Whilst all cardiovascular comorbidities
Fig 5. Cardiovascular comorbidities in heart failure and patient health pathway. In the regression graph an arrow is present between a response and an explanatory
variable if there is a significant association (P< 0.01), controlling for all remaining regressors. The strength of this association is shown as OR (95% CI), if the response
variable is binary, and mean difference (95% CI) in the response variable for a 1-unit increase in the explanatory variable, if the response variable is continuous.
Significant interactions and non-linear relationships are also indicated. Reduced ejection fraction defined as<40%. Pain and anxiety or depression defined as ‘any
problems’. Shortness of breath and fatigue defined as ‘marked or severe’, and functional limitation as ‘any’ limitation in usual activities. Patient-rated health was
measured by EuroQol visual analogue scale, ranging from 0 (worst health imaginable) to 100 (best health imaginable). AF, atrial fibrillation; IHD, ischemic heart
disease; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1002540.g005
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were directly associated with ejection fraction, there was no associations between ejection frac-
tion status and any of the other symptoms or health domains.
Non-cardiovascular comorbidities and patient-rated health
Diabetes, COPD, and CKD had indirect associations with patient-rated health through symp-
toms and functional limitations, but there were variations in symptom associations (Fig 6).
Diabetes and CKD were significantly associated with marked or severe SOB (OR 1.17, 95% CI
1.03 to 1.32, and OR 1.23, 95% CI 1.10 to 1.38, respectively) and fatigue (OR 1.27, 95% CI 1.13
to 1.42, and OR 1.24, 95% CI 1.12 to 1.38) compared to HF patients without these comorbidi-
ties. However, there were no associations for either comorbidity with pain and anxiety or
depression. COPD, in contrast, was associated with all 4 symptoms: SOB (OR 1.84, 95% CI
1.62 to 2.10), fatigue (OR 1.69, 95% CI 1.50 to 1.91), pain (OR 1.34, 95% CI 1.19 to 1.52), and
anxiety or depression (OR 1.21, 95% CI 1.08 to 1.36). As with pain and anxiety or depression,
SOB and fatigue were associated with functional limitations (SOB, OR 1.98, 95% CI 1.74 to
2.26; fatigue, OR 2.45, 95% CI 2.16 to 2.79) (and subsequent worse patient-rated health) and
also had direct associations with patient-rated health (SOB, mean difference in EQ-VAS score,
−6.24, 95% CI −7.30 to −5.14; fatigue, mean difference in EQ-VAS score, −5.53, 95% CI −6.51
to −4.45) that were not explained by functional limitations. Again, ejection fraction did not
explain any of the relationships between comorbidities and the other patient-rated health
domains.
Fig 6. Non-cardiovascular comorbidities in heart failure and patient health pathway. In the regression graph an arrow is present between a response and an
explanatory variable if there is a significant association (P< 0.01), controlling for all remaining regressors. The strength of this association is shown as OR (95% CI), if
the response variable is binary, and mean difference (95% CI) in the response variable for a 1-unit increase in the explanatory variable, if the response variable is
continuous. Significant interactions and non-linear relationships are also indicated. CKD defined as estimated glomerular filtration rate< 60 ml/min/1.73 m2. Reduced
ejection fraction defined as<40%. Pain and anxiety or depression defined as ‘any problems’. Shortness of breath and fatigue defined as ‘marked or severe’, and
functional limitation as ‘any’ limitation in usual activities. Patient-rated health was measured by EuroQol visual analogue scale, ranging from 0 (worst health imaginable)
to 100 (best health imaginable). CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; OR, odds ratio.
https://doi.org/10.1371/journal.pmed.1002540.g006
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Indirect pathways between patient/environmental factors in HF,
comorbidities, and patient-rated health
There were indirect pathways through comorbidities to patient-rated health for age, sex, BMI,
smoking, speciality, and healthcare provider. With few exceptions, older age, higher BMI, and
being an inpatient rather than an outpatient were associated with higher levels of cardiovascu-
lar and non-cardiovascular comorbidities. Women were less likely to have cardiovascular
comorbidities and more likely to have COPD and CKD than men. Compared to general medi-
cine, cardiology care was associated with the presence of some but not all cardiovascular
comorbidities as well as CKD (see S2 Table). ACEi or ARB prescription in HF patients was
associated with reduced fatigue compared to patients not prescribed an ACEi or ARB (OR
0.70, 95% CI 0.59 to 0.82), and those with a device had increased fatigue compared to patients
without a device (OR 1.26, 95% CI 1.09 to 1.45), but there were no other significant associa-
tions between HF optimising therapies (pharmacology or devices) and symptoms, functional
limitations, or patient-rated health (Table 2).
Discussion
Our study used an a priori evidence-informed health model to investigate the potential path-
ways linking comorbidities with patient-reported symptoms, functional limitations, and
patient-rated health in a large population-based registry of over 10,000 patients. The impor-
tance of elucidating these pathways for clinical management is the potential to improve HF
prognosis by tailoring interventions to an individual patient’s risk, pathology, and health.
Uniquely, by using sequences of regressions to separate out direct and indirect associations,
we found that the potential pathways to HF patient health are different for cardiovascular com-
pared to non-cardiovascular comorbidities and among specific comorbid diseases. Impor-
tantly, with minor exception, HF optimising therapies were not associated with symptoms,
functional limitations, or patient-rated health. These key findings provide the evidence for a
step-change in understanding and testing mechanisms between HF and overall patient-rated
health and for developing precision medicine that targets specific comorbidities and associated
symptoms.
There are 3 key findings with important implications for clinical care. First, the main symp-
toms associated with cardiovascular comorbidities were pain and anxiety or depression and
not SOB and fatigue. Notably, despite the high prevalence and severity of SOB and fatigue in
HF generally, around half of all patients reported pain and anxiety or depression, which is sim-
ilar to levels found in hospitalised HF patients [21]. Furthermore, anxiety or depression had
the strongest associations, out of all 4 symptoms, with functional limitations and patient-rated
health. Chronic depression was poorly reported in the SHFR, so the number of people with
chronic or new depression symptoms is likely a lot higher. This means that the association
between depression and functional limitation or poor health may be even greater. Yet, it has
long been recognised that psychosocial factors such as anxiety and depression are infrequently
assessed or treated in HF clinical practice, with only a minority of HF patients with depression
prescribed antidepressant drugs or counselling [22] or referred for cognitive behavioural ther-
apy [29]. Pain is also poorly managed in HF patients, with relatively low use of analgesics or
opioids [22].
Second, the 3 common non-cardiovascular comorbidities (COPD, diabetes, and CKD) were
associated with the highest overall symptom burden and with more severe symptoms than were
associated with cardiovascular comorbidities or with no comorbidities. The predominant symp-
toms associated with COPD, diabetes, and CKD were SOB and fatigue, although COPD was
associated with all 4 symptoms. Explanations for the increase in cardiovascular-related symptoms
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with non-cardiovascular diseases are multiple and varied. It is likely that comorbidities interact
with the HF via conflicts in medications, efficacy of interventions, patient self-care, or shared risk
factors such as obesity and reduced exercise [30].
The implications of both these findings are important. The symptom focus in HF guidelines
and clinical practice is usually on SOB, leg swelling, and fatigue [6]. These symptoms collec-
tively drive clinical management, which focuses on cardiovascular status and associated opti-
misation of therapies, particularly for HF with reduced ejection fraction [31]. Whilst the
management of comorbidities is prioritised for HF patients with preserved ejection fraction,
this likely reflects the failure of the numerous Phase II and III trials to show any convincing
evidence of benefit from standard HF treatments in this group [32]. So, despite the emphasis
on comorbidities for HF patients with preserved ejection fraction, symptoms are not specifi-
cally addressed in guidelines, and the comorbidities included are poorly aligned with symptom
status.
Our findings show that a potential mismatch exists between these guidelines and patient-
rated health, with increased SOB and fatigue being driven by non-cardiovascular status and
pain and anxiety or depression being driven by cardiovascular status. This indicates that, for
HF patients’ health to improve, new interventions for common HF symptoms need to include
the most prevalent non-cardiovascular comorbidities and that management of pain and anxi-
ety or depression needs to become part of routine guideline-driven care and would be an
important addition to clinically relevant end-points in clinical trials.
Our third key finding was that although HF optimising therapies were prescribed for most
SHFR patients, with minor exception, these therapies were not associated directly or indirectly
with comorbidities, symptoms, functional limitations, or patient-rated health. Previous evi-
dence has found only modest benefit from HF pharmacological treatment for quality of life in
HF [33], but we also found a poor relationship between therapies and both symptoms and
functional limitations. Given the strong associations between patient-rated health and out-
comes in HF [3,4], this raises the question of whether HF management needs to be more pre-
cise and tailored to the individual patient’s comorbidity and related symptom status. HF
patients are older (median age 74 years) and experience multiple conditions and a wide range
of symptoms, as indicated by our study, which means that novel multi-condition and multi-
disciplinary approaches to care will be required to improve their prognosis and health [34].
However, such structured or multi-disciplinary care is not part of current guideline recom-
mendations [22].
Strengths and limitations
The SHFR includes patients from most (>85%) hospitals in Sweden as well as primary care
units and covers the full range of patients with preserved and reduced ejection fraction as well
as those with comorbidities, who are often excluded from clinical trials. The availability of
such data meant that an a priori HF health model could be hypothesized and tested to provide
a detailed concept of the potential pathways between comorbidities and patient-rated health in
HF. It is important to note that health measures were only available for a quarter of all patients
entered into the register. Whilst the SHFR was created in 2005, EQ-5D has only been included
as part of baseline registrations since February 2008. There has been a slow increase since then
in the proportion of records completed, particularly in the inpatient setting. Consequently,
our sample was predominantly based in the outpatient setting, and patients were slightly youn-
ger, more often men, more often married, with a reduced ejected fraction, and more frequently
prescribed HF optimising medications. This could imply an underestimation of poor patient-
rated health in our study, as older age groups, women, and patients in hospital reported more
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symptoms than their younger, male, and outpatient counterparts. The impact of such differ-
ences on the complex relationships between comorbidities and health is difficult to estimate;
we took account of these factors in the model, but we cannot rule out unmeasured
confounding.
Whilst patient-rated health in our study was based on EQ-VAS, which is a simple, valid,
and reliable measure of patient’s own health, comorbidities and symptoms were based on clin-
ical recording, which can be subject to misclassification, leading to under-ascertainment. That
said, any such misclassification is likely to bias the associations towards the null value. We
used sequences of regressions for our analyses, meaning that direct and indirect associations
between variables could be exposed that are often hidden by conventional statistical analyses.
However, as with any method of analysis, the validity of any model depends on having consid-
ered the most influential explanatory variables at the outset. The study was retrospective and
observational, with few missing data, but an important limitation was the lack of some relevant
variables that might impact health such as social status/deprivation, emotional, and spiritual
measures. However, our intention was to uncover the indirect relations between comorbidities
and patient-rated health through subjective patient-reported health measures as opposed to
producing a definitive HRQoL model, and we did use a range of clinical, patient, environmen-
tal, and biological variables based on an a priori hypothesized model. Although the investiga-
tion used a cross-sectional design, it provides novel and original findings for a HF health
model that can be further tested in prospective studies and externally validated in different
countries to assess the consistency of relationships postulated by the model.
Conclusions
In HF, distinct health pathways exist among cardiovascular and non-cardiovascular comorbid-
ities that are not influenced by HF optimising therapies. Our HF health model reveals the
potential interplay of different factors that underpin health in HF. These findings highlight the
need to refocus on person-centred HF care and consider the specific mechanisms that contrib-
ute to overall patient health, and to design effective interventions that target the comorbidities
and the range of symptoms with the biggest impact on health.
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